Tryngolza (sHTG)
Get notified when a new coverage update is posted for this brand.
Therapeutic Area
Rare Disease / Lipidology — Severe Hypertriglyceridemia
Primary Competitor
Vascepa / fibrates (standard of care)
Current Watch Item
Triglyceride threshold simplification
Payers with Published Policy
1 backed by a citable published policy document
PA Criteria Defined
Exception Pathway Published
Time to First Policy
Brand Access Summary
Tryngolza (sHTG) is building access faster than FCS given the larger eligible population. The recent trend is favorable: several payers are simplifying triglyceride-threshold documentation and shortening the required diet/lifestyle trial.
Indication-centered view
Policy Posture and UM Summary
| SEGMENT | POLICY POSTURE | COMMON UM CRITERIA | LAUNCH RISK |
|---|---|---|---|
| Commercial | 74% published / 61% PA defined | TG threshold documentation (single qualifying lab value); 3-month diet trial | Documentation is simplifying — risk is now execution speed, not policy language |
| Medicare | 68% published / 55% PA defined | TG threshold plus statin-intolerance or maximally-tolerated-statin documentation | Renewal criteria not yet aligned with initial-authorization simplification |
| Medicaid | 59% published / 44% PA defined | Fibrate step-through varies — removed in some states, still required in others | State-by-state variation is the main access-build risk |
Access build since launch
Launch Access Trend
Brand documents
Shared Documents
PDF, DOC, PNG or JPG · max 20 MB
Uploaded by Maria Chen
Jun 1, 2026
Uploaded by Daniel Ruiz
May 24, 2026
Uploaded by Anika Patel
May 20, 2026